- Home
- RDCM vs CRBP Comparison
RDCM vs CRBP Comparison
Compare RDCM & CRBP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | RDCM | CRBP |
|---|---|---|
| Founded | 1985 | 2009 |
| Country | Israel | United States |
| Employees | N/A | N/A |
| Industry | Computer peripheral equipment | Biotechnology: Pharmaceutical Preparations |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 173.6M | 190.3M |
| IPO Year | 1999 | 2014 |
Fundamental Metrics
Financial Performance| Metric | RDCM | CRBP |
|---|---|---|
| Price | $10.12 | $7.02 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 1 | 6 |
| Target Price | $18.00 | ★ $45.50 |
| AVG Volume (30 Days) | 92.9K | ★ 979.5K |
| Earning Date | 05-13-2026 | 05-08-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $4,822,272.00 |
| Revenue This Year | $11.50 | N/A |
| Revenue Next Year | $9.74 | $116.00 |
| P/E Ratio | $16.35 | ★ N/A |
| Revenue Growth | N/A | ★ 97.62 |
| 52 Week Low | $9.40 | $6.33 |
| 52 Week High | $16.74 | $20.56 |
Technical Indicators
Market Signals| Indicator | RDCM | CRBP |
|---|---|---|
| Relative Strength Index (RSI) | 43.14 | 30.48 |
| Support Level | $9.73 | $6.33 |
| Resistance Level | $10.79 | $8.54 |
| Average True Range (ATR) | 0.27 | 0.70 |
| MACD | 0.06 | -0.13 |
| Stochastic Oscillator | 23.45 | 16.86 |
Price Performance
Historical ComparisonAbout RDCM Radcom Ltd.
Radcom Ltd Ltd is engaged in providing network intelligence, 5G ready cloud-native, network intelligence solutions for telecom operators transitioning to 5G. The company has a network intelligence solution for 5G namely Radcom ACE. Its products consist of Radcom Network Visibility, Radcom Service Assurance, and Radcom Network Insights. It has offices in Israel, the United States, Brazil, and India. Key revenue is derived from sales in North America.
About CRBP Corbus Pharmaceuticals Holdings Inc.
Corbus Pharmaceuticals Holdings Inc is a clinical stage company focused on new therapies in oncology and obesity and is committed to helping people defeat serious illness by bringing inventive scientific approaches to well-understood biological pathways. The company's development pipeline includes; CRB-701, a next-generation antibody-drug conjugate (ADC) that targets the expression of Nectin-4 on cancer cells to release a cytotoxic payload, CRB-601, an anti-integrin monoclonal antibody that blocks the activation of TGF expressed on cancer cells, and CRB-913 a second-generation peripherally restricted CB1 receptor inverse agonist designed to treat obesity.